OZEM Fact Sheet: Roundhill GLP-1 & Weight Loss ETF
Share
$28.76
close, Nov 20, 2026
Over the year to Nov 19, 2026, OZEM returned −8.8% in total and charged 0.59% a year.
- 1-year total return
- −9.2%
- to Nov 20, 2026
- Expense ratio
- 0.59%
- a year
- Net assets
- $53m
- on Nov 20, 2026
- Net flow, last 5 trading days
- $0
- daily basis to Nov 19, 2026
Growth of $10,000, 1 year
OZEM $9,123 −8.8% · Total return, distributions reinvested, Nov 19, 2025 to Nov 19, 2026.
Returns
WindowTotal return
1 month−4.1%
3 months−14.9%
Year to date−15.8%
1 year−9.2%
Since launch+15.0%
Total return, distributions reinvested, each window to Nov 20, 2026.
Ten largest positions
HoldingWeight
Eli Lilly & Co20.55%
Novo Nordisk A/S10.70%
Chugai Pharmaceutical Co Ltd7.38%
Hanmi Pharm Co Ltd7.30%
Pfizer Inc5.85%
CSPC Pharmaceutical Group Ltd4.88%
Kailera Therapeutics Inc4.40%
Jiangsu Hengrui Pharmaceuticals Co Ltd3.93%
Hansoh Pharmaceutical Group Co Ltd3.66%
Viking Therapeutics Inc3.63%
OZEM top ten by weight, 72.3% of the fund, of its 21 equity positions, from the holdings published by its issuer for Nov 20, 2026.
Facts
Holds 21 stocks in healthcare innovation and GLP-1, 31% of its weight in S&P 500 companies · First traded May 21, 2024 · Benchmark Its own holdings, as of Nov 20, 2026; its prospectus names no index it tracks